Research Report on Efferocytosis Features and Their Prognostic and Immunotherapy Associations in Lung Adenocarcinoma Background and Research Motivation Lung cancer is a leading cause of cancer-related mortality worldwide, with lung adenocarcinoma (LUAD) being the most common histological subtype. Due to the insidious nature of the disease and lack ...
Long-term Intravenous Anti-CD20 Antibody Therapy Assessment in a French Multiple Sclerosis Cohort Background and Research Motivation Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease affecting the central nervous system, leading to varying degrees of physical and cognitive impairment. Recent Phase II and III clinical trials of...
Targeting SNRNP200-Induced Splicing Dysregulation: A New Strategy for Immunotherapy in Glycolytic Triple-Negative Breast Cancer Background Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, characterized by extremely high recurrence and mortality rates. Despite significant recent advances in research on TNBC subty...
Epitope Prime Editing Shields Hematopoietic Cells from CD123 Immunotherapy: A Novel Therapeutic Strategy for Acute Myeloid Leukemia Research Background and Problem Statement Acute Myeloid Leukemia (AML) is a malignant blood disease characterized by the abnormal differentiation of myeloid hematopoietic stem and progenitor cells (HSPCs). Its incidenc...
Background Introduction Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, with a five-year survival rate of less than 20%, and treatment options are extremely limited. Traditional targeted drug therapies, such as Sorafenib and other kinase inhibitors, have been used to treat HCC, but their efficacy is limited and diffi...
Fibrotic Response Induced by Anti-CSF-1R Treatment Promotes Glioblastoma Recurrence Background Introduction Glioblastoma (GBM) is a highly aggressive and malignant primary tumor of the central nervous system. Although current standard treatments include surgical resection, Temozolomide chemotherapy, and fractionated radiotherapy, the median surviva...
Fusobacterium nucleatum Promotes Anti-PD-1 Therapy in Microsatellite-Stable Colorectal Cancer Background Introduction With the rise of immune checkpoint blockade (ICB) therapy, a new dawn has emerged in cancer treatment. However, despite the approval of PD-1 targeting drugs (e.g., Pembrolizumab) for certain types of colorectal cancer (CRC) patients...
Proteomic Subtyping of Small Cell Lung Cancer: Analysis of Prognosis and Treatment Strategies Research Background Small Cell Lung Cancer (SCLC) is a highly malignant and heterogeneous cancer characterized by rapid growth, early metastasis, and drug resistance, which limits treatment options and challenges prognostic prediction models. Current genom...
The Key Role of Retina Microglia in Pathological Angiogenesis and the Immunotherapeutic Potential of the cGAS-STING Pathway Background Pathological angiogenesis is common in various neovascular ophthalmic diseases, such as Diabetic Retinopathy (DR) and Age-related Macular Degeneration (AMD) [1]. During these diseases, bone marrow cells, including r...
Immunotherapy Checkpoint Inhibitors (ICIs, also known as immune checkpoint blockers) are a class of drugs that have achieved significant breakthroughs in cancer immunotherapy in recent years. These drugs mainly work by blocking Programmed Death Protein 1 (PD-1) and Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4), thereby activating anti-tumor ...